Cargando…

Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients

SIMPLE SUMMARY: Ongoing clinical trials are recently investigating the efficacy of second-line EGFR inhibitors in initially RAS mutant metastatic colorectal cancer patients who convert to RAS wild-type in plasma, as assessed by circulating tumor DNA (ctDNA) analysis. To this purpose, discriminating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicolazzo, Chiara, Barault, Ludovic, Caponnetto, Salvatore, Macagno, Marco, De Renzi, Gianluigi, Gradilone, Angela, Belardinilli, Francesca, Cortesi, Enrico, Di Nicolantonio, Federica, Gazzaniga, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761880/ https://www.ncbi.nlm.nih.gov/pubmed/33291569 http://dx.doi.org/10.3390/cancers12123633

Ejemplares similares

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study
por: Nicolazzo, Chiara, et al.
Publicado: (2022)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

Prognostic Role of Circulating Tumor Cell Trajectories in Metastatic Colorectal Cancer
por: Magri, Valentina, et al.
Publicado: (2023)

Molecular markers in circulating tumour cells from metastatic colorectal cancer patients
por: Gazzaniga, Paola, et al.
Publicado: (2010)

Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2020)

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
por: Nicolazzo, Chiara, et al.
Publicado: (2016)

Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments
por: Nicolazzo, Chiara, et al.
Publicado: (2021)

EpCAM(low) Circulating Tumor Cells: Gold in the Waste
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

Letter to the Editor: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy”
por: Nicolazzo, Chiara, et al.
Publicado: (2017)

Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal
por: Gradilone, Angela, et al.
Publicado: (2011)

Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo
por: Raimondi, Cristina, et al.
Publicado: (2014)

In vitro cultures of circulating tumor cells: a potential tool to unravel drug sensitivity
por: De Renzi, Gianluigi, et al.
Publicado: (2022)

Sequential Isolation and Characterization of Single CTCs and Large CTC Clusters in Metastatic Colorectal Cancer Patients
por: Francescangeli, Federica, et al.
Publicado: (2021)

Significance of Circulating Tumor Cells in Soft Tissue Sarcoma
por: Nicolazzo, Chiara, et al.
Publicado: (2015)

Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study
por: Sciortino, Carolina, et al.
Publicado: (2022)

Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma
por: Nicolazzo, Chiara, et al.
Publicado: (2018)

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
por: Crisafulli, Giovanni, et al.
Publicado: (2019)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2020)

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report
por: Capalbo, Carlo, et al.
Publicado: (2014)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile
por: De Angelis, Maria Laura, et al.
Publicado: (2022)

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
por: Crisafulli, Giovanni, et al.
Publicado: (2022)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

Birthweight, Maternal Weight Trajectories and Global DNA Methylation of LINE-1 Repetitive Elements
por: Michels, Karin B., et al.
Publicado: (2011)

An Orthotopic Patient-Derived Xenograft (PDX) Model Allows the Analysis of Metastasis-Associated Features in Colorectal Cancer
por: De Angelis, Maria Laura, et al.
Publicado: (2022)

Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study
por: Siringo, Marco, et al.
Publicado: (2023)

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2009)

Burned-Out Testicular Cancer: Really a Different History?
por: Mosillo, Claudia, et al.
Publicado: (2017)

Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer
por: Belardinilli, Francesca, et al.
Publicado: (2020)

Mitochondrial clearance by the STK38 kinase supports oncogenic Ras-induced cell transformation
por: Bettoun, Audrey, et al.
Publicado: (2016)

Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study
por: Tenuta, Marta, et al.
Publicado: (2021)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer
por: Isnaldi, Edoardo, et al.
Publicado: (2019)

The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management
por: Roberto, Michela, et al.
Publicado: (2023)

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
por: Morano, Federica, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5t5k5t5fd4ctbostr3kii2intq